Leukosight, Inc is a privately held biopharmaceutical company developing a novel line of anti-inflammatory therapeutics to address the medical needs of patients with acute or chronic autoimmune/inflammatory diseases. Focusing on small molecule therapeutics and delivery system for rheumatoid arthritis, Crohn’s and asthma.

In July of 2012, LeukoSight, Inc. received Phase I Small Business Technology Transfer funding from the NIH.

New Markets Team Members:

Mark Grovic

Co-Founder and General Partner




Join our Mailing list!

Get all the latest news and updates.